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DSM-IV; SCID I).  Results: Only 11 patients (48%) had a favor-
able follow-up, defined as absence of major depressive epi-
sodes during the observation period. Patients with a favor-
able and an unfavorable course did not differ in clinical or 
sociodemographic parameters, endocrinological results or 
continuation of lithium. However, fewer previous depressive 
episodes tended to correlate (p = 0.09) with a favorable 
course.  Conclusion: Results from studies using the DEX/CRH 
test to predict relapse in depressed patients treated with an-
tidepressants were not replicated for lithium augmentation. 
Our finding could reflect the elevation of DEX/CRH results by 
lithium, independent of clinical course. Limitations of the 
study are its small sample size, the heterogeneous clinical 
baseline conditions and the lack of lithium serum levels. The 
fact that lithium continuation did not predict the course 
might be related to the difference between the efficacy of 
lithium in controlled studies and its effectiveness in natural-
istic settings.  Copyright © 2009 S. Karger AG, Basel 
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 Abstract 
 Background: Lithium augmentation is a first-line strategy 
for depressed patients resistant to antidepressive therapy, 
but little is known about patients’ subsequent long-term 
course or outcome predictors. We investigated long-term 
outcomes of unipolar depressed patients who had partici-
pated in a study on the effects of lithium augmentation on 
the hypothalamic-pituitary-adrenocortical system using the 
combined dexamethasone/corticotrophin-releasing hor-
mone (DEX/CRH) test.  Methods: Twelve to 28 months (mean 
18.6  8 4.6 months) after lithium augmentation, 23 patients 
were assessed with a standardized interview, of which 18 pa-
tients had complete DEX/CRH test results. Relapse was diag-
nosed by DSM-IV criteria (Structured Clinical Interview for 
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 Introduction 
 Lithium augmentation was first described by de Mon-
tigny et al.  [1] . Its clinical evidence and hypotheses on its 
mode of action have been reviewed repeatedly  [2, 3] . Lith-
ium augmentation has been recommended as a first-line 
strategy for depressed patients not responding to stan-
dard antidepressant therapy in evidence-based treatment 
guidelines  [4] . Randomized placebo-controlled trials 
have shown the efficacy of lithium augmentation for dif-
ferent classes of antidepressants  [5–7] . A recent meta-
analysis of 10 randomized placebo-controlled trials con-
firmed that lithium is an effective augmentation strategy 
in patients with depressive disorders, with an odds ratio 
of 3.11, a number needed to treat of 5 and a significantly 
higher rate of responders compared to placebo treatment 
(41.2 vs. 14.4%)  [8] . However, none of the placebo-con-
trolled studies reported data that had been gathered for 
longer than 6 weeks. Therefore, little is known about the 
medium and long-term course of depressed patients who 
underwent lithium augmentation.
 Treatment-refractory depressed patients have a par-
ticularly high risk of relapse  [9, 10] . Because lithium aug-
mentation is typically applied to this group of patients, 
more valid data on the predictors of the long-term course 
of lithium-augmented patients under naturalistic condi-
tions are needed.
 Nierenberg et al.  [11] retrospectively investigated the 
course of 66 patients who had been treated with lithium 
augmentation in a naturalistic design. After a mean fol-
low-up of 29 months, a positive long-term outcome cor-
related only to a fast and positive response to the initial 
lithium augmentation. Shergill et al.  [12] evaluated the 
course of 53 patients out of a sample of 76 patients from 
2 controlled studies on lithium augmentation 4–8 years 
after treatment. Seventy-two percent of the sample had a 
good course (defined as the absence of hospitalization 
due to affective illness), which correlated with an absence 
of previous hospitalizations, a smaller degree of ‘endoge-
neity’ and with non-continuation of lithium medica-
tion.
 We reported results from a double-blind placebo-con-
trolled study of lithium augmentation in continuation 
therapy with a double-blind phase of 4 months and a sub-
sequent open-label phase of 6 months  [13, 14] . In the latter 
trial, patients taking an antidepressant combined with 
lithium had a significantly lower risk of relapse than pa-
tients taking an antidepressant combined with placebo.
 Studies available on the follow-up of acute lithium 
augmentation do not examine social stressors as media-
tors of relapse, nor do they explore endocrinological vari-
ables, both of which are important as the correlation of 
long-term course with social variables  [15–17] and endo-
crinological parameters [e.g.  18, 19 ] is indicated by a wide 
variety of studies.
 The hypothalamic-pituitary-adrenocortical (HPA) 
system is putatively the best-studied biological system in 
affective disorders with the development and course of 
depression being linked to central regulation impairment 
of the HPA system  [20, 21] . Previous research has estab-
lished the dexamethasone/corticotrophin-releasing hor-
mone (DEX/CRH) test as the most sensitive challenge 
test for identifying HPA dysfunction  [21] . The procedure 
of the DEX/CRH test has been described in detail else-
where  [22] .
 Using the combined DEX/CRH test, Zobel et al.  [18, 
19] examined 74 inpatients who had recently recovered 
from a major depressive episode after antidepressant 
pharmacotherapy. A higher cortisol reaction in the DEX/
CRH test predicted a relapse in the 6-months follow-up. 
Furthermore, in a comparison of the DEX/CRH test at 
hospital admission with a test performed shortly before 
discharge (after successful acute treatment), patients with 
a later relapse (n = 13) showed an increase in cortisol re-
sponse. In contrast, the 61 patients who remained stable 
during follow-up displayed a decrease in the mean corti-
sol response.
 In particular, we investigated the relationship between 
the HPA system and the clinical course during the obser-
vation period. In the current study, we performed a fol-
low-up investigation of 30 patients who were treated with 
lithium augmentation within a study investigating the 
acute outcome of lithium augmentation and endocrino-
logical correlates (‘initial study’). Eleven patients re-
sponded within the initial study according to predefined 
criteria [decrease in Hamilton Depression Rating Scale 
17-item score (HDRS-17)  ^  50% and total HDRS-17 score 
 ! 10]. Both responders and non-responders showed a sig-
nificant increase in cortisol and adrenocorticotropic hor-
mone (ACTH) response from the first to the second DEX/
CRH test.
 In the current study, we evaluated the course of the ill-
ness over a follow-up period with a mean length of 18 
months under naturalistic conditions, and tried to iden-
tify clinical, therapeutic and psychosocial variables, as 
well as important life events, during the follow-up period 
as outcome predictors. Results of the acute treatment 
phase (4 weeks), which focused on the HPA system, have 
been published elsewhere  [22, 23] .
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 Method 
 Subjects 
 Twenty-three of the 30 patients of the initial study (77%) were 
available for the follow-up investigation. Six patients could not be 
interviewed because they had moved abroad (n = 2) or to an un-
known location (n = 4); 1 patient declined participation in the 
follow-up interview. Seventeen of the 23 patients were interviewed 
face-to-face, and the other 6 by telephone.
 In the initial study, 30 unipolar depressed patients, who were 
refractory to a trial with an antidepressant (minimum dosage of 
150 mg imipramine equivalent) of at least 4 weeks, were subse-
quently treated with lithium augmentation. All patients were di-
agnosed as suffering from a major depressive episode according 
to DSM-IV (confirmed by SCID I; German version  [24] ). In the 
initial study, a combined DEX/CRH test was performed the day 
before lithium augmentation was started, and the test was repeat-
ed 2–4 weeks later. Response was determined by weekly ratings 
with the HDRS-17  [25] .
 The study protocol was approved by the Ethics Committee of 
the Medical Faculty of the Freie Universität Berlin.
 Data Collection 
 All eligible patients of the initial study were contacted by 
phone or mail and examined in a standardized face-to-face inter-
view no less than 1 year after the end of the initial study. Current 
lithium treatment was not an inclusion criterion for the follow-up 
study. All those participating in the present follow-up investiga-
tion received a financial reimbursement of EUR 25. If a face-to-
face interview was not possible, a telephone interview was carried 
out.
 After the patients had given written consent (none refused), 
additional information was obtained from the charts and reports 
of in- and outpatient clinics or private practices where they had 
been treated during the follow-up period.
 The following information was collected: 
 • Clinical course of the affective disorder or any other psychiat-
ric disorder. For all phases of a possible psychiatric illness dur-
ing the follow-up period, the SCID I interview was applied to 
confirm diagnosis. 
 • Course of treatment during the follow-up period with regard 
to in- and outpatient treatment, psychotherapy and pharma-
cotherapy; with special attention to information about con-
tinuation or withdrawal of the lithium medication. 
 • Suicide attempts and suicides. 
 • Present social situation: living circumstances, financial situa-
tion, occupational status. 
 • Non-psychiatric diseases and treatment during the follow-up 
period. 
 • Important life events, systematically evaluated with the List of 
Threatening Events Questionnaire  [26] . 
 • Mental status and depression severity (HDRS-17). 
 Further parameters ascertained during the initial study were 
also taken into the analyses: the ACTHpeak and  cortisol peak values 
in the DEX/CRH test during lithium augmentation and the dif-
ference in  cortisol peak ( change cortisol peak ) between the first (pri-
or to lithium augmentation) and the second (under ongoing lith-
ium augmentation) DEX/CRH test.
 Outcome Criterion 
 The clinical course was classified as favorable if, according to 
DSM-IV, no major depressive episode occurred during the follow-
up period. If a major depressive episode occurred (relapse or re-
currence), the course was classified as unfavorable. Accordingly, 
patients with no remission throughout the entire follow-up peri-
od (n = 3) were also classified as having an unfavorable outcome. 
Although this strategy implies some obvious methodological 
shortcomings, for reasons of statistical power we decided not to 
split the sample into 3 different groups. The follow-up period was 
defined as the time span from hospital discharge (after the end of 
the initial study) to the date of the follow-up investigation. In ad-
dition, univariate and logistic regression analysis for only the first 
12 months of follow-up was performed to assess all subjects (with 
varying follow-up intervals ranging from 12 to 28 months) for a 
comparable period of time.
 Statistical Analysis 
 Univariate differences between patients with a favorable out-
come and those with an unfavorable outcome were assessed using 
the Mann-Whitney U test or, in the case of dichotomous vari-
ables, using Fisher’s exact test. In order to confirm the univariate 
results, a logistic regression analysis (simultaneous inclusion) 
with the demographic, illness- and treatment-related variables 
and a second logistic regression analysis with the endocrinologi-
cal parameters were performed. The following parameters were 
included in the first analysis to consider the major factors that 
contribute to treatment outcomes: age and gender, duration of 
index episode until start of lithium augmentation, number of pre-
vious depressive episodes, response status in the initial lithium 
augmentation study and the duration of continued lithium intake 
during the follow-up period. Because the individual follow-up pe-
riods varied, the duration of continued lithium intake during the 
follow-up period was expressed as the ratio of the duration of lith-
ium intake during the follow-up period (in weeks)/duration
of the follow-up period (in weeks ) . The second analysis included 
as potential predictors: the  change cortisol peak and change
ACTH peak between the first DEX/CRH test and the second DEX/
CRH test, as well as the peak cortisol and ACTH concentrations 
( cortisol peak ; ACTH peak ) in the second DEX/CRH test.
 Results 
 Study Population 
 Figure 1 shows the changes in study population from 
the initial study to the current one. The 23 patients inter-
viewed (12 female and 11 male) were aged 50.8  8 16.3 
years at the time of the follow-up interview. On average, 
they had 2.6  8 3.0 depressive episodes and 1.4  8 1.4 psy-
chiatric hospitalizations prior to the index episode (i.e. 
initial study). In the initial study, 9 of the 23 patients had 
been classified as responders and 14 as non-responders to 
lithium augmentation. The follow-up investigation was 
performed at an average of 18.6  8 4.6 months (range: 
12–28) after termination of the initial study.
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 Outcome during the Follow-Up Period 
 Eleven of the 23 patients (48%) experienced no major 
depressive episodes (favorable outcome) and 12 (52%) had 
an unfavorable outcome during the follow-up period.
 Of the 12 patients with an unfavorable course, 2 had a 
relapse within the first 6 months after recovery, and 6 suf-
fered from a later recurrence. Among the latter, 2 patients 
actually had 2 depressive recurrences. Three of the 12 pa-
tients (non-responders in the initial study) developed a 
chronic course of the depression and did not reach remis-
sion within the entire follow-up period, although they 
had been discharged from the psychiatric hospital. One 
patient exhibited a manic episode 13 weeks after the end 
of the initial study and a following depressive recurrence 
30 weeks later. Subsequently, his diagnose was changed 
to bipolar disorder. The depressive relapses and recur-
rences occurred in a wide time span ranging from 8.5 to 
80.0 weeks after the end of the initial study (mean: 46.4 
 8 28.2 weeks).
 Nine of the 12 patients with an unfavorable course had 
to be re-hospitalized during the follow-up period, 4 of 
them twice. Two of the 12 had attempted suicide (wrist 
cut and intoxication with tablets, respectively), but no pa-
tient had died from suicide.
 Demographic, Illness and Treatment-Related 
Variables 
 According to the univariate analyses, patients with a 
favorable and an unfavorable outcome did not differ in a 
statistically significant way with regard to demographic, 
illness or treatment-related variables ( table 1 ). Age, gen-
der, age at first depressive episode and duration of the 
index episode prior to lithium augmentation were not 
significantly different. It is noteworthy that the course 
experienced by responders to the initial lithium augmen-
tation was not better during follow-up than that of non-
responders. The duration of continued lithium intake 
during the follow-up period (in percent of the duration of 
the individual follow-up period) was comparable in both 
groups (29%). During 54% of the time of the follow-up 
period, patients were taking at least 1 antidepressant (no 
significant group difference). A similar number of pa-
tients with favorable (55%) and unfavorable follow-ups 
(58%) underwent psychotherapy. Thirteen of the 23 pa-
tients had experienced at least 1 life event according to the 
List of Threatening Events Questionnaire; 6 with a favor-
able and 7 with an unfavorable follow-up. In detail, 6 life 
events were the death of a relative, 3 a severe somatic ill-
ness, 3 the ending of a relationship, 2 a severe financial 
crisis, 2 a severe familial or partnership conflict and 2 
patients had been victims of a crime.
 Patients with a favorable course, however, tended to 
have fewer previous depressive episodes (1.8  8 2.9) com-
pared to those with an unfavorable course (3.2  8 3.0;
p = 0.09, univariate analysis). Not surprisingly, the pa-
tients with an unfavorable follow-up had a significantly 
higher HDRS-17 score at the interview compared to the 
stable group (p = 0.02).
 Endocrine Variables 
 Five of the 23 patients had refused re-assessment with 
the combined DEX/CRH test in the initial study; there-
fore, full information on the HPA system parameters was 
only available for 18 patients (9 with a favorable and
9 with an unfavorable course). As shown in  table 2 ,
ACTHpeak and  cortisol peak values in the DEX/CRH test 
during ongoing lithium augmentation appeared to be 
higher in patients with a subsequent unfavorable course 
compared to patients with a favorable course ( ACTH peak : 
38.7  8 34.6 vs. 32.6  8 29.1 pg/ml;  cortisol peak : 103.3  8 
77.5 vs. 71.6  8 39.8 ng/ml). However, differences were 
not statistically significant. Apart from the peak values, 
  values (peak value minus baseline value) and area un-
der the curve (AUC) values were also used to quantify the 
30 23 18
Initial sample size Sample size available for
follow-up study
Favorable outcome: n = 12 
Unfavorable outcome: n = 11
Sample size available
with completed
DEX/CRH test
 Fig. 1. Availability of the study population 
from the initial study for the follow-up in-
vestigation. 
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Table 1. Demographic, illness and treatment-related variables of 23 patients with major depressive disorder who were followed up af-
ter lithium augmentation
Total
(n = 23)
Favorable
course
Unfavorable
course
Univariate
p values
(n = 11) (n = 12)
Gender (female:male) 12:11 6:5 6:6 1.0
Age at follow-up, years 50.8816.3 48.8815.8 52.6817.2 0.53
Length of follow-up interval, months 18.684.6 17.384.9 19.884.2 0.13
Responders to lithium augmentation in the initial study 9 5 4 0.68
Number of previous depressive episodes 2.683.0 1.882.9 3.283.0 0.09
Number of previous psychiatric hospitalizations 1.481.4 1.081.2 1.881.5 0.21
Age at onset of mood disorder, years 37.7816.5 37.6817.0 37.9816.8 0.93
Duration of index episode up to start of lithium augmentation, weeks 44.9850.1 46.4856.2 43.6846.5 0.98
HDRS-17 prior to lithium augmentation 20.384.0 19.083.6 21.484.1 0.13
HDRS-17 at the beginning of the follow-up period 12.787.4 11.487.0 13.988.0 0.45
HDRS-17 at follow-up 8.585.9 5.283.8 11.586.0 0.02
Duration of continued lithium intake, weeks 22.5829.4 18.9827.0 25.9832.3 0.65
Ratio of duration of continued lithium intake/duration of follow-up 0.2980.38 0.2980.41 0.2980.37 0.93
Ratio of duration of intake of at least 1 antidepressant/duration of follow-up 0.5480.33 0.6080.36 0.4980.31 0.46
Specific psychotherapy during the follow-up period 13 (57) 6 (55) 7 (58) 1.0
Life events during the follow-up period1 13 (57) 6 (55) 7 (58) 1.0
Working 9 (39) 6 (55) 3 (25) 0.21
Living alone 11 (48) 4 (36) 7 (58) 0.41
Data presented as means 8 SD or numbers (percentages). Favorable course = No major depressive episode according to DSM IV 
(SCID I validated) at any time during the follow-up period. For dichotomous variables, Fisher’s exact test was used to calculate the p 
values, for all other variables the Mann-Whitney U test was used. 
1 Assessed by the List of Threatening Events Questionnaire.
Table 2. ACTH and cortisol responses to the combined DEX/CRH test before and after lithium augmentation in patients with a sub-
sequent favorable or unfavorable course
Total Favorable
course 
Unfavorable
course
Univariate
p values
Response in the combined DEX/CRH test before onset of LA, n 23 11 12
ACTHpeak, pg/ml 20.0811.1 21.4814.2 18.787.8 0.98
Cortisolpeak, ng/ml 63.8842.3 61.5842.6 65.9843.7 0.88
Response in the combined DEX/CRH test after onset of LA, n 18 9 9
ACTHpeak, pg/ml 35.7831.2 32.6829.1 38.7834.6 1.0
Cortisolpeak, ng/ml 87.5862.0 71.6839.8 103.3877.5 0.60
Changes in endocrine response between the first and the second DEX/CRH test
Change ACTHpeak, pg/ml +16.0823.4 +11.2817.3 +20.8828.6 0.67
Change cortisolpeak, ng/ml +27.5846.4 +12.1829.6 +43.0856.3 0.30
Data presented as means 8 SD, with all p values calculated by the Mann-Whitney U test. Favorable course = No major depressive 
episode according to DSM IV (SCID I validated) at any time during the follow-up period. LA = Lithium augmentation.
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cortisol and ACTH response to the CRH injection in the 
DEX/CRH test. These parameters also did not show a 
significant difference between patients with a favorable 
and with an unfavorable follow-up (data not shown in 
detail).
 As described previously, the cortisol and ACTH re-
sponse in the combined DEX/CRH test was significantly 
stronger during lithium augmentation compared to the 
pre-lithium baseline investigation  [22] . This applied to 
patients with a favorable as well as to patients with an un-
favorable follow-up. Interestingly, in the latter group this 
increase seemed to be more prominent. The  change cor-
tisol peak  was + 12.1  8 29.6 ng/ml in the favorable and + 
43.0  8 56.3 ng/ml in the unfavorable follow-up group. 
However, this did not result in a significant difference. 
Differences between the 2 groups for ACTH response and 
for the   and AUC values were not significant either (data 
not shown in detail).
 Logistic Regression 
 The logistic regression analysis with favorable/unfa-
vorable course as the dependent variable and with a 
multi-step inclusion of the demographic, illness and 
treatment-related parameters mentioned above (n = 23) 
did not reveal a significant model. Nor did the second lo-
gistic regression analysis with the endocrinological pa-
rameters (n = 18) yield a significant model.
 Outcome in the First 12 Months of Follow-Up 
 The follow-up interval of the patients ranged from 12 
to 28 months. Accordingly, subjects with a longer follow-
up period were at a greater risk of recurrence. Although 
the length of the follow-up interval was comparable be-
tween patients with a favorable and with an unfavorable 
course (17.3  8 4.9 and 19.8  8 4.2 months, respectively), 
we repeated all univariate and logistic regression analy-
ses, restricting them to the first 12 months of the follow-
up period (data not shown in detail). Four patients (all 
female) were stable in the first 12 months, but experi-
enced a later recurrence. Hence, in this analysis 15 pa-
tients were classified as having a favorable and 8 as having 
an unfavorable outcome.
 With regard to statistical significance, results were not 
different compared to the analysis of the full follow-up 
interval. Interestingly, gender and living alone appeared 
to be different between patients with a favorable and an 
unfavorable course. Six out of 11 men, but only 2 out of 
12 women had an unfavorable course in the first 12 
months (univariate p = 0.089; logistic regression analysis: 
p = 0.057). In addition, 6 out of 11 patients who lived 
alone, but only 2 out of 12 who did not, suffered from a 
major depressive episode in the first year of the follow-up 
interval (similarly, univariate p = 0.089; logistic regres-
sion analysis: p = 0.057).
 Discussion 
 We present a follow-up investigation of a study (‘initial 
study’) of unipolar depressed patients who were resistant 
to a treatment trial with an antidepressant of at least 4 
weeks and who had subsequently been treated with lith-
ium augmentation. Twenty-three of 30 (77%) of the initial 
study population was recruited for the follow-up investi-
gation. This figure is in range of the recruiting rates of 
other studies dealing with lithium augmentation follow-
up, i.e. 70%  [12] or 88%  [11] . Neuroendocrine data were 
available for 18 patients.
 The outcome of the follow-up period is sobering. More 
than half of the patients (52 %) had an unfavorable course 
according to the predefined criteria, with no difference 
in clinical, sociodemographic or endocrinological pa-
rameters nor with regard to the duration of continuation 
treatment with lithium compared to patients with a fa-
vorable course. However, it should be taken into account 
that the patients of this study are a selected group of se-
verely ill patients: all patients had been hospitalized for 
the treatment of the index episode, which in turn had 
lasted for a considerably long period of 44.9  8 50.1 weeks 
on average, and by definition the patients had been re-
fractory to at least 1 trial of antidepressive pharmaco-
therapy prior to lithium augmentation. Therefore, and in 
view of the small sample size, this result cannot be gen-
eralized. Furthermore, the results reflect a course under 
naturalistic conditions. Not all patients may have re-
ceived optimal treatment during the follow-up period, 
and some received no treatment.
 An unexpected result of the study is that neither re-
sponse to initial lithium augmentation nor continued in-
take of lithium correlated with a favorable outcome dur-
ing the follow-up period. This result is in line with find-
ings on the long-term course after a major depressive 
episode and the intake of antidepressants  [16] , but is in 
contrast to the well-established efficacy of lithium to pre-
vent affective relapses in controlled and naturalistic stud-
ies  [27] which was previously confirmed for the continu-
ation therapy phase of lithium augmentation  [13, 15] . 
However, a discrepancy between the efficacy in con-
trolled studies and the effectiveness in the naturalistic 
use of lithium has been repeatedly discussed  [28–34] . 
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This incongruity may contribute to the outcome in the 
study presented here. If so, the results do not question the 
use of lithium, but rather emphasize the need to improve 
the naturalistic outpatient care.
 Neither the demographic nor clinical variables were 
correlated with the outcome during the follow-up period. 
This result conforms with previous studies on this topic 
 [11, 12] . Patients with an unfavorable outcome displayed 
a trend towards a history of more depressive episodes. 
This trend is not surprising and probably reflects a more 
active course of the disease in this group. Living alone has 
been reported to be associated with a higher prevalence 
of depression  [35] . With restriction to the first year of the 
follow-up period, our sample showed a non-significant 
trend for a worse course for patients who lived alone.
 The endocrinological results of the combined DEX/
CRH test also did not predict the course during the fol-
low-up period. Comparable to the study of Zobel et al.  [18, 
19] in antidepressant-treated patients, the patients with 
an unfavorable follow-up had higher cortisol values in the 
second DEX/CRH test. The effect size of the difference in 
 cortisol peak  response was calculated as 0.67, which is be-
tween the conventions of a medium and large group effect 
 [36] . However, we failed to demonstrate a significant 
group difference. This might be due to the small sample 
size or to the lithium comedication. Furthermore, Zobel 
et al.  [18, 19] only investigated the continuation treatment 
phase (6 months). However, when restricting the analysis 
of our study to a 6-month follow-up, the endocrinological 
results do not differentiate between patients with favor-
able or unfavorable follow-up (data not shown).
 A substantial difference of our study to previous stud-
ies which show the association of a favorable long-term 
outcome with normalization of HPA system activity is 
that our sample was investigated under the conditions of 
a lithium challenge. Lithium medication could influence 
the predictive value of the DEX/CRH test. We have 
shown in the ‘initial study’ that lithium application re-
sults in an elevation of the DEX/CRH test response com-
pared to baseline and does not reflect clinical response 
 [22] . This effect of lithium has been described to be in-
dependent of psychopathological state or improvement. 
The relapse predictive value of the DEX/CRH test might 
therefore not be generalizable to antidepressant-treated 
patients with lithium comedication. Replication of our 
study with a larger number of subjects would be worth-
while. We also see the need for larger long-term follow-
up studies of lithium-augmented patients under natural-
istic conditions with regard to factors that modify the 
long-term course.
 It is generally worth noting that after the initial find-
ings suggesting a correlation of DEX/CRH test findings 
and clinical course a lack of relationship between the res-
toration of HPA system dysfunction and acute treatment 
response has also been reported  [37] . Single substances, 
such as lithium in this study, may also ‘break the rules’ as 
has been reported for mirtazapine  [38] .
 Aside from the sample size, there are several other 
limitations of the study. Due to the study design, subjects 
started the follow-up interval under different clinical 
conditions: either depressed or remitted. Furthermore, 
lithium was prescribed in a naturalistic non-standard-
ized manner. Exact lithium doses and serum levels were 
not documented. Reliable data on the appropriateness or 
length of lithium treatment during the follow-up period 
are not available, and may have affected the clinical re-
sults.
 In conclusion, the study results indicate that substan-
tial effort needs to be made to stabilize the course of de-
pressed patients after lithium augmentation in the acute 
treatment phase. Although we cannot replicate the re-
lapse predictive findings from patients treated without 
lithium, it seems noteworthy that, as in other studies, we 
find patients with an unfavorable course after treatment 
of a major depressive episode to have higher cortisol and 
ACTH values in the combined DEX/CRH test.
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